Efficacy and Plasma Drug Concentrations With Nondaily Dosing of Rosuvastatin

Goldberg, Alyse S.; DeGorter, Marianne K.; Ban, Matthew R.; Kim, Richard B.; Hegele, Robert A.

doi:10.1016/j.cjca.2012.12.015

Cited by 10 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Goldberg et al (2013) (9) : The study included 58 patients on rosuvastatin 3-4 times weekly (mean dose of 29.4 ± 14.6mg per week) at a specialty lipid. Patients had a significant reduction in LDL of 34.4 ± 21.3% (P < 0.001) at week 12 from baseline.…”

Section: Three To Five Times a Weekmentioning

confidence: 99%

Efficacy and Tolerability of non-daily Statin Administration: A Systematic Review of Literature

Park

2019

J Contemp Pharm Pract

View full text Add to dashboard Cite

Current issues regarding biosimilar drug use are reviewed in a two-part article from the perspective of pharmacy practice. Background Statins are known to be safe, but some patients discontinue the therapy due to adverse effects. Given the clinical benefits of statin therapy, it is important to find different strategies to maintain its use. The aims of this systematic review were to summarize and critically appraise evidence of the efficacy, tolerability, and economic evaluation of non-daily statin administration in the past ten years. Methods Literature was searched through Cochrane, Embase, PubMed and Web of Science using relevant search terms. Studies of any size and design published between January 2007 and August 2017 were considered for the assessment of efficacy and tolerability. For economic evaluation, the search was repeated without restriction to the publication year to identify more relevant articles. Results All eleven studies, of which three were randomized controlled trials, supported the use of intermittent statin regimens to lower low-density lipoprotein (LDL) levels in patients with dyslipidemia. Most of the studies reported high tolerability to intermittent statin therapy, ranging from 72.5% to 100%. Economic analysis of four articles showed that the intermittent regimen is cost-saving in terms of cost per 1% LDL reduction. Conclusion Our systematic review of current evidence suggests that patients with dyslipidemia may reduce their LDL levels with intermittent statin administration. Non-daily administration has other benefits of improved tolerability and lower cost when compared to daily administration.

show abstract

Section: Three To Five Times a Weekmentioning

confidence: 99%

Efficacy and Tolerability of non-daily Statin Administration: A Systematic Review of Literature

Park

2019

J Contemp Pharm Pract

View full text Add to dashboard Cite

show abstract

“…Goldberg et al 9 found that rosuvastatin concentrations in patients allocated to nondaily dosing were similar to those in patients taking the same tablet size on a daily basis. It follows that this statin-intolerant population must have had higher than normal statin concentrations when they were receiving the more frequent (daily) dosing regimen.…”

mentioning

confidence: 95%

“…In this issue of the Canadian Journal of Cardiology, Goldberg et al 9 describe a retrospective study of patients who could not tolerate daily statin dosing, but who were successfully treated using nondaily dosing. Over the past decade, the concept of nondaily dosing of statins has been supported by several published reports.…”

mentioning

confidence: 99%

Nondaily Statin Dosing: Mechanisms of a Potentially Important Approach to Dealing With Statin Intolerance

Pollak

2013

Canadian Journal of Cardiology

View full text Add to dashboard Cite

“…For example, slow release fluvastatin XL 80 mg daily was tolerated by 97% of patients with prior (muscle‐related) ‘statin intolerance’ symptoms, and LDL‐C was reduced by 32.8% . Goldberg et al . conducted a retrospective study of patients unable to tolerate a daily statin who were successfully treated using non‐daily statin dosing.…”

Section: Statin Reintroductionmentioning

confidence: 99%

“…Non‐daily rosuvastatin lowered LDL‐C by 34 ± 21%, P < 0.001. The ‘non‐daily dosing’ strategy may be better described as an ‘extended dosing interval’, which is associated with lower drug levels and larger swings in drug concentrations . Non‐daily dosing is better with atorvastatin and rosuvastatin, which have longer elimination half‐lives .…”

Section: Statin Reintroductionmentioning

confidence: 99%

Suggested clinical approach for the diagnosis and management of ‘statin intolerance’ with an emphasis on muscle‐related side‐effects

Sivashanmugarajah

Fulcher

Sullivan

et al. 2019

Internal Medicine Journal

View full text Add to dashboard Cite

Hyperlipidaemia is a major risk factor for cardiovascular morbidity and mortality. 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors ('statins') are first-line therapies for hyperlipidaemia. For each 1.0 mmoL/L reduction in low-density lipoprotein (LDL)-cholesterol, statins reduce the risk of major vascular events by 21% and all-cause mortality by 9%. Owing to their clinical effectiveness and excellent safety profile, many Australians are prescribed statins. There has been widespread reporting of possible sideeffects, particularly muscle pains. Conversely, statin cessation relating to possible sideeffects exposes patients to increased risk of vascular events and death. Although there is clinical consensus for diagnosing rare side-effects (e.g. myopathy or rhabdomyolysis), confirming that statins cause other less common side-effects (e.g. memory impairment) is difficult as strong randomised trial evidence related to statins and non-muscle-related side-effects is lacking. A stepwise approach to possible statin intolerance, consistent definitions and a simple flowchart may improve diagnosis and management. An increasing array of potential treatments is emerging, including intermittent statin dosing, new LDLlowering drugs, LDL apheresis and supplements. Optimal statin use and management of statin intolerance should improve cardiovascular care and clinical outcomes.

show abstract

Efficacy and Plasma Drug Concentrations With Nondaily Dosing of Rosuvastatin

Cited by 10 publications

References 21 publications

Efficacy and Tolerability of non-daily Statin Administration: A Systematic Review of Literature

Efficacy and Tolerability of non-daily Statin Administration: A Systematic Review of Literature

Nondaily Statin Dosing: Mechanisms of a Potentially Important Approach to Dealing With Statin Intolerance

Suggested clinical approach for the diagnosis and management of ‘statin intolerance’ with an emphasis on muscle‐related side‐effects

Contact Info

Product

Resources

About